AiCure

R&D Trends

Cleveland Clinic unveils Top 10 Medical Innovations for 2015

Monday, November 3, 2014 02:41 PM

Cleveland Clinic, a nonprofit multispecialty academic medical center that integrates clinical and hospital care with research and education, has announced its 9th annual list of Top 10 Medical Innovations likely to have major impact on improving patient care in 2015. The list of up-and-coming technologies and drug therapies was selected by a panel of 110 Cleveland Clinic physicians and scientists. The Top 10 Medical Innovations for 2015 are:

More... »


Novo Nordisk invests $126M in new Denmark diabetes research labs

Monday, November 3, 2014 02:38 PM

Novo Nordisk has invested approximately $126 million in new laboratories at the company's R&D campus in Måløv, Denmark. Construction has started, and the new laboratory facility is expected to be ready in early 2016.

More... »

CenterWatch

Impax to reorganize R&D, cut 49 jobs

Monday, November 3, 2014 02:32 PM

Impax Laboratories, a Hayward, Calif.-headquartered, technology-based specialty pharmaceutical company, is cutting about a quarter of its R&D work force—42 of a total of 49 job cuts—as part of an R&D reorganization and prioritization of project portfolios within the generic and brand businesses.

More... »

Five foundations to participate in Cavendish Global Health Impact Forum

Friday, October 31, 2014 02:18 PM

Cavendish Global has selected five foundations to participate in the Cavendish Global Health Impact Forum taking place Nov. 10-13 at Oxford University in the U.K. The selected organizations and the participating representatives include:

More... »

Profectus BioSciences receives $9.5M Department of Defense funding for Ebola

Friday, October 31, 2014 02:16 PM

The Department of Defense (DoD), through the Medical Countermeasure Systems-Joint Vaccine Acquisition Program (MCS-JVAP), has contracted the manufacture and IND-enabling preclinical testing of the Profectus trivalent Ebola/Marburg vaccine. Profectus BioSciences is a Baltimore, Md.-based clinical-stage vaccine company developing novel vaccines for the treatment and prevention of infectious diseases.

More... »

Cancer Innovation Coalition calls for reinvigorated U.S. cancer innovation

Friday, October 31, 2014 02:10 PM

The Cancer Innovation Coalition (CIC) has gone to Capitol Hill to call for early legislative and regulatory action in 2015 that will reinvigorate cancer innovation in the U.S.

More... »

MD Anderson Moon Shots Program begins to generate innovations

Friday, October 31, 2014 02:07 PM

Improved surgical outcomes for ovarian cancer, expanded potential impact for new drugs and a novel family outreach program to head off cancers fueled by known genetic risk mutations are among the early innovations of the University of TexasMD Anderson Cancer Center's Moon Shots Program.

More... »

Merck discontinues tecemotide clinical program

Friday, October 31, 2014 02:03 PM

Merck will discontinue the clinical development program of its investigational MUC1 antigen-specific cancer immunotherapy tecemotide (also known as L-BLP25) as a monotherapy in stage III non-small cell lung cancer (NSCLC).

More... »

Report: Orphan drug market to reach $176B by 2020

Thursday, October 30, 2014 12:19 PM

In 2020 orphan drugs are expected to account for 19% of the total share of prescription drug sales excluding generics, reaching $176 billion in annual sales, according to the new EvaluatePharma Orphan Drug Report 2014 from London-based market intelligence firm Evaluate.

More... »

U.S. government institutes funding pause on gain-of-function research

Wednesday, October 29, 2014 01:39 PM

The U.S. government will undertake a deliberative process to assess the risks and benefits of certain gain-of-function (GOF) experiments with influenza, SARS and MERS viruses in order to develop a new federal policy regarding the funding of this research, announced Francis S. Collins, M.D., Ph.D., NIH director, in a statement. U.S. government agencies will institute a pause on the funding of any new studies involving these experiments.

More... »

Link to survey
CLINICAL TRIAL RESOURCES

Search:

NEWS ONLINE ARCHIVE

Browse by:

CWWeekly

November 24

Tufts CSDD’s $2.6 billion price tag to develop and bring a new drug to market raises questions, criticisms

Medidata joins GlaxoSmithKline in study to evaluate the impact of wearing mobile devices in clinical trials

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

November

Private equity driving dynamic CRO growth
Enables CROs to pursue long-term strategies, while giving the space credibility

Baby boomers poised to reshape clinical trials industry
Millions of tech-savvy consumers already track their health, expect new treatments as they age

Already a subscriber?
Log in to your digital subscription.

Purchase the September issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly

October

CROs driving changes in patient recruitment
Data- and tech-aided enrollment services a competitive advantage

Trials with in-home nurses poised to grow
Higher expense, but may improve recruitment and retention for select trials

Already a subscriber?
Log in to your digital subscription.

Purchase the October issue.

Subscribe to
The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs